BioBridge Global Launches BBG Advanced Therapies Subsidiary
January 02, 2025
BioBridge Global, an
AABB corporate partner, officially
launched BBG Advanced Therapies, a new operating subsidiary to consolidate its cell and gene therapy services portfolio, on Jan. 1. This new subsidiary consolidates the organization’s cell and gene therapy services into a single, integrated entity designed to simplify operations and enhance customer experience.
BBG Advanced Therapies combines biomanufacturing, process development and tech transfer services from GenCure; cell therapy testing and analytical development from QualTex Laboratories; and leukapheresis, starting materials and clinical research support from South Texas Blood and Tissue.
Adrienne Mendoza, MHA, who has been with BioBridge for nine years and previously served as chief operating officer (COO) of South Texas Blood and Tissue, will lead BBG Advanced Therapies as COO. She brings extensive experience in blood components, regulatory affairs and cell-based therapies.
As Mendoza transitions into her new role, South Texas Blood and Tissue will be led by Mark Fite, an operating executive with more than 35 years of experience, assisted by Col. Audra Taylor, SBB, (U.S. Army retired), who previously served as the division chief of the Armed Services Blood Program for the Defense Health Agency.
